Is Peptide Receptor Radionuclide Therapy Effective in the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer?-A Case Report.
Peptide receptor radionuclide therapy (PRRT) is getting attention for tough thyroid cancer cases that don’t respond to standard radioactive iodine. A new case report out of Turkey puts PRRT under the microscope for radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC), a diagnosis that leaves researchers hunting for better options.
Niger J Clin Pract
by Çelik A, Şengöz T
“Is Peptide Receptor Radionuclide Therapy Effective in the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer?-A Case Report. Çelik A(1), Şengöz T. Author information: (1)Department of Nuclear Medicine, Pamukkale University Faculty of Medicine, Pamukkale, Denizli, Türkiye. Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) represents a major clinical challenge due to its limited response to conventional treatment and poor prognosis. Peptide receptor radionuclide therapy (PRRT) has emerged as a promising treatment modality in patients with somatostatin receptor (SSTR)-positive tumors. We present an 82-year-old female patient with RAIR-DTC who underwent six cycles of PRRT after demonstrating SSTR positivity on Ga-68 DOTATATE positron emission tomography/computed tomography. This case highlights the limited therapeutic efficacy of PRRT in RAIR-DTC, despite favorable imaging characteristics. It underscores the need for better patient selection and further research to clarify the role of PRRT in this population. Copyright © 2026 Nigerian Journal of Clinical Practice.”
Here’s what happened: An 82-year-old woman with RAIR-DTC had tumors lighting up on a Ga-68 DOTATATE PET/CT scan, showing strong somatostatin receptor (SSTR) activity. That’s the green light for PRRT, which targets those same receptors. The research team ran her through six cycles of PRRT.
Key takeaway: Even with textbook SSTR-positivity, PRRT didn’t deliver the results researchers hoped for in this case. The tumor didn’t respond as expected. The researchers point out that just because a tumor shows up on SSTR imaging doesn’t guarantee a major clinical response to peptide-based therapies like PRRT.
Why does this matter for peptide research? This case throws more fuel on the debate about how to select patients for PRRT and similar peptide-targeted therapies. It’s not a story of failure—it’s a data point reminding the research community that matching the right compound to the right tumor isn’t always as simple as a positive scan. More precise biomarkers or combination approaches may be needed.
For researchers interested in PRRT, somatostatin analogs, and thyroid cancer, this report highlights the value of ongoing experimentation:
SSTR imaging is essential, but not the whole story
Patient selection for PRRT is still an open research question
The search for new peptide-based approaches in RAIR-DTC is active and evolving
Peptide research isn’t slowing down—cases like this just show how much more there is to learn.
Related Reading
Reply: Semaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment.
News · JACC Heart FailSemaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment.
News · NeuropsychopharmacologyIdentification of an intrusive-hypervigilant phenotype of posttraumatic stress symptoms with unique stress peptide and amygdala functional connectivity profiles.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.